Для специалистовДля граждан
 

The 4th Leading International Conference on Immunotherapy of Cancer



Дата начала мероприятия: 
20.03.2017
Дата окончания мероприятия: 
22.03.2017

4th Immunotherapy of Cancer Conference (ITOC4)

20 – 22 March 2017
Prague, Czech Republic

About ITOC

The Immunotherapy of Cancer Conference is the leading international conference on immunotherapy of cancer organized in Europe by CDDF in collaboration with SITC. The conference reunites preclinical and clinical scientists, academia, healthcare professionals and the pharmaceutical industry in a forum to discuss early clinical drug developments and address the unique challenges of immunotherapy.

The concept is timely and necessary as agents have been licensed and arrived in clinical practice and many more similar drugs are expected to follow.

ITOC  is designed to provide a highly interactive platform. In so doing, it attracts a multi-stakeholder attendance connecting preclinical and clinical scientists, clinicians, healthcare professionals, academia and other stakeholders who are involved in the development of novel anticancer agents. ITOC is renowned within its audience for the highly scientific character of its lectures.

The 4th Leading International Conference on Immunotherapy of Cancer in Europe!

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) have the great pleasure to invite you to take part in the 4thImmunotherapy of Cancer Conference (ITOC4) – the leading international conference providing a global platform in Europe for translational research in the field of immuno-oncology.

The ITOC series of conferences is the premier meeting for education, scientific exchange and networking within cancer immunotherapy.
The fourth edition (ITOC4) will take place on Prague, Czech Republic, from 20 to 22 March 2017.
It aims at providing a forum for all professionals working in immunotherapy to discuss early clinical drug development and address the unique challenges of translational research.
The programme will focus on the latest challenges and innovations with a special emphasis on combination therapy, immuno-monitoring and biomarker development.

At this conference, we are in particular addressing preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals and the pharmaceutical industry.

Help us spread the word! Download and share this advert! PDF version